Therapeutics
Caveo Therapeutics currently has a pipeline of products for the treatment of hematologic malignancies as well as metastatic disease. Lead candidates were identified following in vivo preclinical studies and are currently undergoing lead optimization.

Reagents
In order to support the research community striving to better understand this important area of cancer biology, we also provide 2 superior research reagents, highly specific monoclonal antibodies to the Mer receptor tyrosine kinase.

CVO-311, CVO-312
Binding of the ligand Gas6 to the Mer receptor tyrosine kinase (RTK) triggers receptor dimerization and phosphorylation, thereby regulating tyrosine kinase activity. Mer is expressed in many tissues including kidney, lung, ovary, testis, and prostate. Within hematopoietic lineages, Mer is normally expressed in macrophages, monocytes, dendritic cells and platelets and plays a significant role in macrophage clearance of apoptotic cells, platelet aggregation, and cell survival. Abnormal Mer expression is also detected in many human cancers including leukemia and lymphoma. CVO-311 (specification sheet) and CVO-312 (specification sheet) are each highly specific, murine monoclonal antibodies which recognize the extracellular domain of the human Mer RTK. These reagents are particularly suitable for western blotting applications.

CVO-311 Format/Formulation: affinity-purified $250 Storage: 2-8°C/-20°C (long term storage) 0.4 ml Specification Sheet - PDF - 75KB   CVO-312 Format/Formulation: affinity-purified $250 Storage: 2-8°C/-20°C (long term storage) 0.4 ml Specification Sheet - PDF - 57KB     Note: Online orders are shipped priority overnight for delivery to locations within the U.S. ONLY. For shipments outside the U.S., please email info@caveotherapeutics.com for personal assistance. American Express and Visa/MC debit cards are also accepted.